Related Experiment Video
Updated: Sep 1, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
Emma Boswell Dean1, Amelia M Bond2
1Department of Health Management and Policy, Miami Herbert Business School, University of Miami, Miami, Florida.
Abstract:
This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.
Related Concept Videos
Bioequivalence: Overview
Drug Biotransformation: Overview
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Biopharmaceutics and Pharmacokinetics: Overview
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

